NasdaqCM - Nasdaq Real Time Price • USD
Mereo BioPharma Group plc (MREO)
At close: May 31 at 4:00 PM EDT
After hours: May 31 at 6:16 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2019) | Next Qtr. (Mar 2020) | Current Year (2019) | Next Year (2020) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2019) | Next Qtr. (Mar 2020) | Current Year (2019) | Next Year (2020) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | 1 | 1 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | 4.4M |
| High Estimate | -- | -- | -- | 4.4M |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | ||||
|---|---|---|---|---|
| EPS Est. | -- | -- | -- | -- |
| EPS Actual | -- | -- | -- | -- |
| Difference | -- | -- | -- | -- |
| Surprise % | -- | -- | -- | -- |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Dec 2019) | Next Qtr. (Mar 2020) | Current Year (2019) | Next Year (2020) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | -0.26 | 0 | -0.47 | -52 |
| 30 Days Ago | -0.26 | 0 | -0.47 | -52 |
| 60 Days Ago | -0.26 | 0 | -0.47 | -52 |
| 90 Days Ago | -0.26 | 0 | -0.47 | -52 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Dec 2019) | Next Qtr. (Mar 2020) | Current Year (2019) | Next Year (2020) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | 1 | -- |
| Up Last 30 Days | -- | -- | 1 | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | MREO | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -- | -- | -- | 7.70% |
| Next Qtr. | -- | -- | -- | 10.10% |
| Current Year | -- | -- | -- | 4.60% |
| Next Year | -- | -- | -- | 12.50% |
| Next 5 Years (per annum) | -- | -- | -- | 11.29% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 5/16/2024 |
| Reiterates | Needham: Buy to Buy | 5/16/2024 |
| Reiterates | Needham: Buy to Buy | 4/10/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 3/28/2024 |
| Maintains | Needham: Buy to Buy | 3/28/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 3/22/2024 |
Related Tickers
PDSB PDS Biotechnology Corporation
2.9800
+1.02%
XFOR X4 Pharmaceuticals, Inc.
1.0100
+3.49%
DAWN Day One Biopharmaceuticals, Inc.
13.27
-2.43%
IMVT Immunovant, Inc.
25.39
-3.86%
EFTR eFFECTOR Therapeutics, Inc.
1.6000
-5.88%
CLRB Cellectar Biosciences, Inc.
3.0900
+1.64%
XERS Xeris Biopharma Holdings, Inc.
2.2550
+1.58%
AFMD Affimed N.V.
4.3500
+7.14%
ADAP Adaptimmune Therapeutics plc
1.1300
+11.88%
CYTK Cytokinetics, Incorporated
48.51
-1.24%